Wells Fargo Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

By Carrie Williams

Wells Fargo analyst David Maris maintained a Buy rating on Jazz Pharmaceuticals (JAZZResearch Report) today. The company’s shares closed last Monday at $133.26.

According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.5% and a 39.5% success rate. Maris covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Establishment Labs Holdings Inc, and Osmotica Pharmaceuticals Plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $177.50 average price target, which is a 31.8% upside from current levels. In a report issued on August 7, Barclays also maintained a Buy rating on the stock with a $180 price target.

See today’s analyst top recommended stocks >>

Jazz Pharmaceuticals’ market cap is currently $7.75B and has a P/E ratio of 12.34. The company has a Price to Book ratio of 2.60.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.